

# A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines

NCT07492277

---

**Status** RECRUITING  
**Sponsor** Croma-Pharma GmbH  
**Enrollment** 70 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Participants deemed by the treating physician to have LCL and/or PR of sufficient severity to merit treatment with croma revitalis to be corrected and treatment decision is reached independent of this study.
- Male or female, 18 years of age or older at Visit 1 (Day 0).
- Healthy skin in the facial area and free of diseases that could interfere in cutaneous aging evaluation, based on the physician's judgment.
- Participants who, according to routine clinical advice, are willing to refrain from undergoing any aesthetic or surgical procedures in the treatment area during the observation period.
- Participants who understand the purpose and nature of the observational data documentation and willingness to participate in the routine follow-up after 3, 5, 8, 12, and 24 weeks as judged by the treating physician.

... and 1 more (see full listing online)

### Exclusion (25)

- Participants who tend to develop hypertrophic scars, have pigment disorders, or have susceptibility to keloid formation.
- Participants with a history of autoimmune disease or who are receiving therapy for modification of immune response, e.g., biologics, systemic corticosteroids, cytostatic drugs (from Visit 1 \[Day 0\] until the end of the study).
- Participants who are known to be hypersensitive to components of the device as HA, glycerol, or gram-positive bacterial proteins.
- Participants who are pregnant or breast feeding.
- Participants who are anticoagulated or with history of bleeding disorder.

... and 20 more (see full listing online)

## Locations (1 total)

---

Yuvell, Vienna, Austria